Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Psychiatric disorders in neurology.
Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: the contribution of mindfulness-based interventions.
Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.
Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies.
Towards establishing MS prevalence in Latin America and the Caribbean.
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.
Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.
Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System.
Progressive resistance therapy is not the best way to rehabilitate deficits due to multiple sclerosis: No.
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo.
From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development.
Safety and efficacy extension study of daclizumab high yield process (DAC HYP) to treat relapsing remitting multiple sclerosis
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
Reward responsiveness and fatigue in multiple sclerosis.
Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress.
The microglial sensome revealed by direct RNA sequencing.
Gray matter is targeted in first-attack multiple sclerosis.
Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses.
Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.
Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-Aquaporin 4 antibodies.
Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation.
Behavioral interventions in multiple sclerosis: a biopsychosocial perspective.
Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72.
Pages
« first
‹ previous
…
175
176
177
178
179
180
181
182
183
…
next ›
last »